Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Launched by NATIONAL CANCER INSTITUTE (NCI) · Nov 14, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Stereotactic Body Radiation Therapy (SBRT) for men with a single tumor in their prostate, which is a common type of prostate cancer. The goal is to find out how well this treatment works in targeting the cancer while causing fewer side effects compared to traditional treatments like surgery or standard radiation. To participate, men must be at least 18 years old and have been diagnosed with localized prostate cancer that hasn’t spread beyond the prostate. They should also not have high-risk features in their cancer, and a few other health conditions may disqualify them.

If you join the study, you will first undergo some tests, including blood work and imaging scans, to ensure you’re a good candidate. Then, tiny gold seeds will be placed near the tumor to help guide the radiation during two treatment sessions, each lasting about 1-2 hours. The sessions are painless, and you can go home afterward. Over the next two years, you’ll have follow-up appointments with more scans and tests to monitor your health and the effect of the treatment. This trial could be a promising option for men looking for effective prostate cancer care with potentially fewer side effects.

Gender

MALE

Eligibility criteria

• * INCLUSION CRITERIA:
• • Participants must have histologically confirmed, low or intermediate risk prostatic adenocarcinoma verified by biopsy (NIH Laboratory of Pathology confirmation is required).
• • Unifocal prostate cancer defined as a single focus of prostate cancer on MRI and PSMA PET/CT imaging which is correlated with a positive targeted biopsy.
• • Age \>=18 years.
• • ECOG performance status \<=2 (Karnofsky \>60%).
• • Men must agree to use highly effective contraception with their partner (barrier method of birth control; abstinence) for the duration of study participation and up to 120 days after the last radiation treatment.
• • Ability of individual to understand and the willingness to sign a written informed consent document.
• EXCLUSION CRITERIA:
• • Participants with NCCN high-risk prostate cancer features (Gleason score \>=8, \>cT2c, or PSA \>= 20 ng/mL).
• • Participants with prostate biopsies which show \>= grade group 2 adenocarcinoma determined to be outside of the radiographically visible lesion (systematic biopsies which map to a radiographically detected lesion are not an exclusion criterion).
• • Participants in whom concurrent systemic Androgen Deprivation Therapy (ADT) or chemotherapy is planned.
• • Participants who are receiving any other investigational agents.
• • Participants found to have pelvic or distant metastases on pre-treatment staging studies.
• • Participants with an AUA-SI/IPSS score \> 18.
• • Participants who have previously received curative treatment for a prior or the current diagnosis of prostate cancer.
• • Active urinary tract infection assessed by urinalysis.
• • Human immunodeficiency virus (HIV)-infected individuals who are not on effective anti-retroviral therapy. Participants on anti-retroviral therapy with undetectable viral load within the 6 months prior to registration are eligible for this trial.
• • Participants with hepatitis B virus (HBV) infection who have not been treated and cured.
• • Participants with chronic HBV at screening must have an undetectable HBV viral load on suppressive therapy.
• • Participants with hepatitis C virus (HCV) infection who have not been treated and cured.
• • Participants with HCV infection who are currently on treatment, are eligible if they have an undetectable HCV viral load at screening.
• • Anatomic relationship between the tumor and adjacent normal tissues judged to be unfeasible for the planned treatment by the PI.
• • Participants with connective tissue diseases.
• • Participants with radiation hypersensitivity syndromes.
• • Ongoing active inflammatory bowel disease within the radiation field.
• • Participants with prior medical comorbidity or surgical history involving the low pelvis which is expected to confer a high risk of toxicity to the experimental radiation regimen.
• • Ineligibility or unwillingness to undergo a contrast-enhanced MRI due to inadequate renal function (eGFR \< 30), severe claustrophobia, a weight above tolerance of the scanner (\> 350 lbs.), a body size unable to fit into the scanner, or implanted devices incompatible with an MRI (implanted cardiac devices, surgical hardware, retained shrapnel, cerebral aneurysm clips, or other incompatible objects.
• • Unwillingness to undergo an 18F-DCFPyL PET/CT or known allergy to the 18F-DCFPyL tracer.
• • Contraindication or inability to undergo fiducial marker implantation.
• • History of prior radiotherapy overlapping with the intended radiation field.
• • Uncontrolled intercurrent illness, factors, or social situations that would limit compliance with study requirements.